August 29, 2024 07:17 AM EDT

Preclinical team hit hardest in Repare's R&D prioritization, layoffs

Katherine Lewin

News Reporter

Repare Therapeutics is cutting its headcount by about 25%, with most of the layoffs concentrated in the company’s preclinical team, as part of what the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Preclinical team hit hardest in Repare's R&D prioritization, layoffs

Katherine Lewin

News Reporter

Sign up to read this article for free.

Over a year after FDA rejection, Biohaven claims success in pivotal muscle disease study

Q&A: Bristol Myers’ tech chief on the promises and perils of AI bio

AstraZeneca, Daiichi’s TROP2 drug misses overall survival goal in Phase 3 breast cancer trial

UCB adds three more FDA approvals to label for potential blockbuster Bimzelx

Telix buys radiopharmacy network for $230M up front to expand US capacity

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships

Pre­clin­i­cal team hit hard­est in Re­pare's R&D pri­or­i­ti­za­tion, lay­offs

Katherine Lewin

News Reporter

Sign up to read this article for free.

Over a year af­ter FDA re­jec­tion, Bio­haven claims suc­cess in piv­otal mus­cle dis­ease study

Q&A: Bris­tol My­ers’ tech chief on the promis­es and per­ils of AI bio

As­traZeneca, Dai­ichi’s TROP2 drug miss­es over­all sur­vival goal in Phase 3 breast can­cer tri­al

UCB adds three more FDA ap­provals to la­bel for po­ten­tial block­buster Bimzelx

Telix buys ra­dio­phar­ma­cy net­work for $230M up front to ex­pand US ca­pac­i­ty

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

Preclinical team hit hardest in Repare's R&D prioritization, layoffs

Over a year after FDA rejection, Biohaven claims success in pivotal muscle disease study

Q&A: Bristol Myers’ tech chief on the promises and perils of AI bio

AstraZeneca, Daiichi’s TROP2 drug misses overall survival goal in Phase 3 breast cancer trial

UCB adds three more FDA approvals to label for potential blockbuster Bimzelx

Telix buys radiopharmacy network for $230M up front to expand US capacity

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships